Emerging Adverse Cutaneous Drug Reactions
| Autor: | Joshua W. Hagen, A. Neil Crowson, Cynthia M. Magro |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Tumor Necrosis Factor-alpha business.industry Antibodies Monoclonal Immunoglobulins Intravenous Interferon-alpha Antineoplastic Agents Dermatology Antigens CD20 Receptors Tumor Necrosis Factor Infliximab Chronic disease Levamisole medicine Humans Hydroxyurea Immunologic Factors Interleukin-2 Drug Eruptions Drug reaction Intensive care medicine Adverse effect business medicine.drug |
| Zdroj: | Dermatologic Clinics. 30:695-730 |
| ISSN: | 0733-8635 |
| DOI: | 10.1016/j.det.2012.06.016 |
| Popis: | The past several decades have seen the advent and rapidly expanding use of biological agents in the treatment of chronic disease states. As increasingly large pools of patients have been enrolled in treatment protocols using these agents, physicians have become acquainted with both desired and adverse events associated with their use. Dermatologists frequently encounter patients affected by cutaneous drug reactions associated with the use of biological agents, thereby becoming familiar with the full range of side effects reported in the literature. This review discusses these adverse cutaneous effects, their underlying mechanisms, and efforts to predict and minimize their occurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|